Literature DB >> 14574532

Urine and serum free IGF-1 levels in patients with bladder cancer: a brief report.

T Ahmet Serel1, Tahir Turan, Sedat Soyupek, Zafer Aybek, Hakki Perk.   

Abstract

Insulin-like growth factor (IGF)-1, a mitogenic and anti-apoptotic peptide, can affect the proliferation of epithelial cells, and is thought to play a role in cancer development. The free IGF-1 represents the biologically active fraction of IGF-1. We hypothesised that there is a difference in free IGF-1 levels in the urine and serum from patients with TCC and normal subjects. Urine and blood samples were collected from 30 cases of superficial TCC and an equal number control subjects without malignancy. Free IGF-1 levels were measured in duplicate by radioimmunoassay. Specimens of bladder carcinoma were staged histopathologically using the Mostoffi grading system. Statistical analyses were performed using the Mann-Whitney U-test, Pearson correlation and covariate analysis. There was no significant difference in urine and serum free IGF-1 levels between the two groups. The correlation between urine and serum free IGF-1 levels and age was not significant. There was also no significant relationship between free IGF-1 levels and histopathological grading. The results of this pilot study reveal that the free IGF-1 level does not help predict tumour marker in the patients with bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14574532     DOI: 10.1007/s00240-003-0335-0

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  22 in total

1.  Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency.

Authors:  A Juul; K Holm; K W Kastrup; S A Pedersen; K F Michaelsen; T Scheike; S Rasmussen; J Müller; N E Skakkebaek
Journal:  J Clin Endocrinol Metab       Date:  1997-08       Impact factor: 5.958

Review 2.  Growth factors in the regulation of pericellular proteolysis: a review.

Authors:  M Laiho; J Keski-Oja
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

3.  Radioimmunoassay of serum IGF-I and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia.

Authors:  J C Wu; W H Daughaday; S D Lee; T S Hsiao; C K Chou; H D Lin; Y T Tsai; B N Chiang
Journal:  J Lab Clin Med       Date:  1988-11

4.  Measurement of serum ferritin by a 2-site immunoradiometric assay.

Authors:  L E Miles; D A Lipschitz; C P Bieber; J D Cook
Journal:  Anal Biochem       Date:  1974-09       Impact factor: 3.365

5.  Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.

Authors:  J Ma; M N Pollak; E Giovannucci; J M Chan; Y Tao; C H Hennekens; M J Stampfer
Journal:  J Natl Cancer Inst       Date:  1999-04-07       Impact factor: 13.506

6.  Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene.

Authors:  H Werner; E Karnieli; F J Rauscher; D LeRoith
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

7.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.

Authors:  J M Chan; M J Stampfer; E Giovannucci; P H Gann; J Ma; P Wilkinson; C H Hennekens; M Pollak
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

8.  Somatomedin-C levels in growth-impaired children and adolescents with chronic inflammatory bowel disease.

Authors:  B S Kirschner; M M Sutton
Journal:  Gastroenterology       Date:  1986-10       Impact factor: 22.682

9.  Characterization of insulin-like growth factor I binding sites in human bladder cancer cell lines.

Authors:  M Iwamura; M Ishibe; P M Sluss; A T Cockett
Journal:  Urol Res       Date:  1993-01

10.  Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index.

Authors:  A Juul; P Bang; N T Hertel; K Main; P Dalgaard; K Jørgensen; J Müller; K Hall; N E Skakkebaek
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

View more
  5 in total

Review 1.  Targeting IGF1R pathway in cancer with microRNAs: How close are we?

Authors:  Arathy S Kumar; Suresh K Rayala; Ganesh Venkatraman
Journal:  RNA Biol       Date:  2018-02-01       Impact factor: 4.652

2.  Interaction network analysis of differentially expressed genes and screening of cancer marker in the urine of patients with invasive bladder cancer.

Authors:  Baihong Guo; Tuanjie Che; Baoguang Shi; Lijun Guo; Zhihua Zhang; Lin Li; Chuanyong Cai; Yirong Chen
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  Screening and identification of specific markers for bladder transitional cell carcinoma from urine urothelial cells with suppressive subtractive hybridization and cDNA microarray.

Authors:  Baihong Guo; Tuanjie Che; Baoguang Shi; Lijun Guo; Yongsheng Yin; Lin Li; Jinming Wang; Dongwen Yan; Yirong Chen
Journal:  Can Urol Assoc J       Date:  2011-01-13       Impact factor: 1.862

4.  Changes of Serum Trace Elements, AFP, CEA, SF, T3, T4 and IGF-II in Different Periods of Rat Liver Cancer.

Authors:  Hong-Xu Zhang; Dan-Dan Liu; Bai-Jie Jin; Ya-Wei Wang; Qi Liu; Ru-Bing Duan; Peng Zhao; Ming-Xia Ma
Journal:  Chin J Cancer Res       Date:  2011-12       Impact factor: 5.087

5.  The Association between Metabolic Syndrome and High-Stage Primary Urothelial Carcinoma of the Bladder.

Authors:  Kei Nagase; Shohei Tobu; Shuhei Kusano; Kohei Takahara; Kazuma Udo; Mitsuru Noguchi
Journal:  Curr Urol       Date:  2018-06-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.